The U.S. Food and Drug Administration has approved ozanimod (Zeposia) for the treatment of relapsing forms of MS, including clinically isolated syndrome (CIS), RRMS and active SPMS. The drug was developed by Receptos, then acquired by Celgene before Celgene was acquired in turn by Bristol-Myers Squibb. Ozanimod was submitted for review by Health Canada in December 2019. Read More
Latest News
Slide deck: COVID-19 – Epidemiology in Canada (April 14, 2020)
April 14, 2020Summary of epidemiology, testing and mortality rate; Canada and world statistics.
COVID-19 – FDA approves hydroxychloroquine amid controversy
April 9, 2020The U.S. Food and Drug Administration has authorized hydroxychloroquine for emergency use for the treatment of patients with COVID-19 infection. Efficacy of the drug for COVID-19 is supported by anecdotal evidence and Donald Trump, but the approval is considered controversial. Novartis/Sandoz has donated 30 million doses and Bayer has donated 1 million tablets of chloroquine phosphate. Read More
MS and coronavirus have a long history
April 9, 2020The human coronavirus (HCoV) is now considered an emerging pathogen but its links to multiple sclerosis date back some 40 years. Read More